GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevena Inc (NAS:TRVN) » Definitions » Gross Margin %

Trevena (Trevena) Gross Margin % : -340.00% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Trevena Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Trevena's Gross Profit for the three months ended in Mar. 2024 was $-0.07 Mil. Trevena's Revenue for the three months ended in Mar. 2024 was $0.02 Mil. Therefore, Trevena's Gross Margin % for the quarter that ended in Mar. 2024 was -340.00%.


The historical rank and industry rank for Trevena's Gross Margin % or its related term are showing as below:

TRVN' s Gross Margin % Range Over the Past 10 Years
Min: -68.25   Med: 70.32   Max: 822.01
Current: 46.53


During the past 13 years, the highest Gross Margin % of Trevena was 822.01%. The lowest was -68.25%. And the median was 70.32%.

TRVN's Gross Margin % is ranked worse than
64.21% of 746 companies
in the Biotechnology industry
Industry Median: 59.74 vs TRVN: 46.53

Trevena had a gross margin of -340.00% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Trevena was 0.00% per year.


Trevena Gross Margin % Historical Data

The historical data trend for Trevena's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trevena Gross Margin % Chart

Trevena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 94.07 -68.25 822.01 46.56

Trevena Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,016.67 97.09 2.78 1,662.20 -340.00

Competitive Comparison of Trevena's Gross Margin %

For the Biotechnology subindustry, Trevena's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trevena's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trevena's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Trevena's Gross Margin % falls into.



Trevena Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Trevena's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=1.5 / 3.125
=(Revenue - Cost of Goods Sold) / Revenue
=(3.125 - 1.67) / 3.125
=46.56 %

Trevena's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-0.1 / 0.02
=(Revenue - Cost of Goods Sold) / Revenue
=(0.02 - 0.088) / 0.02
=-340.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Trevena  (NAS:TRVN) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Trevena had a gross margin of -340.00% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Trevena Gross Margin % Related Terms

Thank you for viewing the detailed overview of Trevena's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Trevena (Trevena) Business Description

Traded in Other Exchanges
Address
955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA, USA, 19087
Trevena Inc is an American biopharmaceutical company focused on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders.
Executives
Mark Corrigan director
Mark Demitrack officer: SVP, Chief Medical Officer 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Robert T Yoder officer: SVP, Chief Business Officer 955 CHESTERBROOK BOULEVARD, SUITE 110, SUITE 200, CHESTERBROOK PA 19087
Carrie L. Bourdow director, officer: President & CEO C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Patricia M. Drake officer: SVP, Chief Commercial Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Barry Shin officer: SVP, CFO C/O TREVENA, INC., 955 CHESTERBROOK BLVD, SUITE 110, CHESTERBROOK PA 19087
Marvin Johnson director C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Moulder Leon O Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Jason Raleigh Nunn director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Scott Applebaum officer: CLCO; SVP, Regulatory Affairs C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
John P. Hamill officer: Int. Prin. Fin. Off. and PAO 4092 NEW HOPE ROAD, FURLONG PA 18925